ClinicalTrials.gg
RecruitingNCT05651919MOBIUpdated Mar 27, 2026

PBMC as Biomarkers of Diabetic Cardiomyopathy

An observational study in Type 2 Diabetes, Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
175
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 2 by Hospices Civils de Lyon — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Hospices Civils de Lyon.

Started
2023
the only one that year
Observational
4 of 15
1 open now
Registered
12th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 2 by Hospices Civils de Lyon, this one is the only one that started in 2023, is one of 4 observational ones, and was the 12th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 15 studies in Diabetes Mellitus, Type 2 by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 2 by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Type 2 diabetes (T2D), especially when associated with metabolic syndrome (MS) is at high risk to develop heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF), and the specific impact of T2D+MS in cardiac function impairment is usually known as "diabetic cardiomyopathy" (DC). Cardiac remodelling (ie hypertrophy) and subtle myocardial dysfunction are highly prevalent in T2D+MS but not specific enough to predict further HFpEF or HFmrEF. Also, current biomarkers can identify but do not predict HFpEF or HFmrEF in T2D patients; Furthermore, specific biomarkers are needed. Peripheral blood mononuclear cells (PBMC) obtained from a peripheral blood sample can provide insights from calcic and inflammatory pathways, and may identify more specific molecular signatures shared between T2D+MS and HFpEF.

03

Conditions studied

  • Type 2 Diabetes
  • Metabolic Syndrome
  • Heart Failure With Preserved Ejection Fraction
  • Heart Failure With Mildly Reduced Ejection Fraction

Keywords

  • Type 2 diabetes
  • metabolic syndrome
  • Heart Failure with Preserved Ejection Fraction
  • heart failure with mildly reduced ejection fraction
  • PBMC
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients coming at hospital for a routine visit

Eligibility criteria

Inclusion Criteria:

Inclusion criteria common to the 4 groups:

  • Patient attending a scheduled cardiology or endocrinology follow-up visit
  • Patient fasting for blood sampling
  • Male or female aged 40 to 85 years inclusive
  • Patient not opposing participation in this research
  • Patient agreeing to the storage of biological samples and to genetic analyses

Group 1: No-T2D +MS / No-HF (control group)

- Patient without T2D or MS and without heart failure coming to a consultation or day hospital for another reason (e.g. screening for atypical symptom, etc.)

Group 2: No-T2D +MS / HFpEF or HFmrEF

  • Patient without T2D or MS
  • HFpEF or HFmrEF. diagnosed

Group 3: T2D+MS / no-HF

  • Patient diagnosed with T2D+MS
  • - Absence of HF

Group 4: T2D +MS / HFpEF or HFmrEF

  • Patient diagnosed with T2D and MS
  • HFpEF or HFmrEF. diagnosed

Exclusion Criteria:

Non-inclusion criteria common to the 4 groups:

  • History of cardiovascular disease (valvular disease [greater than moderate severity], radiation-induced, post-cardiotoxic chemotherapy, amyloidosis, etc.) other than HFpEF or HFmrEF
  • Acute or ongoing systemic inflammatory or infectious disease
  • History of known coronary artery disease
  • Uncontrolled hypertension (>160/100 mmHg)
  • Pregnant or breastfeeding women (based on interview)
  • Persons deprived of liberty by judicial or administrative decision
  • Persons undergoing psychiatric care
  • Patient under legal protection (guardianship or curatorship)
  • Subject participating in another interventional study with an ongoing exclusion period
  • Chronic kidney disease ( \<30 mL/min/1.73 m²)

Group 1: No-T2D +MS / No-HF (control group)

  • Presence of diabetes (whatever the type) and MS
  • Presence of heart failure or other known heart disease

Group 2: No-T2D +MS / HFpEF or HFmrEF

  • Presence of diabetes (whatever the type) and MS
  • (LVEF) on ultrasound ≤ 40%

Group 3: T2D+MS / no-HF

  • Without diabetes or other type of diabetes than T2D
  • Presence of Heart failure (all types)

Group 4: T2D +MS / HFpEF or HFmrEF

  • Absence of diabetes or presence of another type of diabetes than T2D
  • LVEF on ultrasound ≤ 40%
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
175 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • No-T2D +MS / No-HF (control group)

    50 patients without T2D +MS and without Heart Failure will be included in group 1.

    Biological: Blood test · Behavioral: quality of life Questionnaire · Behavioral: Diet habits questionnaire

  • No-T2D +MS / HFpEF or HFmrEF

    25 patients without T2D+MS and presenting HFpEF or HFmrEF will be included in group 2

    Biological: Blood test · Behavioral: quality of life Questionnaire · Behavioral: Diet habits questionnaire

  • T2D+MS / no-HF

    50 patients presenting T2D +MS and without any type of HF will be included in group 3.

    Biological: Blood test · Behavioral: quality of life Questionnaire · Behavioral: Diet habits questionnaire

  • T2D +MS / HFpEF or HFmrEF

    50 patients presenting T2D +MS and HFpEF or HFmrEF will be included in group 4.

    Biological: Blood test · Behavioral: quality of life Questionnaire · Behavioral: Diet habits questionnaire

Interventions

  • BiologicalBlood test

    During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.

  • Behavioralquality of life Questionnaire

    During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life. This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code; Levels of perceived problems are coded as follows: * Level 1 is coded as a '1' (indicating no problem) * Level 2 is coded as a '2' (indicating some problems) * Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems.

  • BehavioralDiet habits questionnaire

    During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits. This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients.

06

What researchers measure

Primary outcomes

  1. Comparison of Initial level of Ca2+ fluxes from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF

    The calcic profile of PBMC will be quantified by flow cytometry to determine the values of the kinetics parameters of Ca2+ fluxes (initial level).

    Time frame: Day of blood sample (inclusion visit)

  2. Comparison of amplitude of Ca2+ fluxes from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF

    The calcic profile of PBMC will be quantified by flow cytometry to determine the values of the kinetics parameters of Ca2+ fluxes (amplitude).

    Time frame: Day of blood sample (inclusion visit)

  3. Comparison of area under curve of Ca2+ fluxes from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF

    The calcic profile will be quantified by flow cytometry to determine the values of the kinetics parameters of Ca2+ fluxes (area under curve).

    Time frame: Day of blood sample (inclusion visit)

  4. Comparison of slope of the response to pharmacological stimulation of Ca2+ fluxes from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF

    The calcic profile of PBMC will be quantified by flow cytometry to determine the values of the kinetics parameters of Ca2+ fluxes (slope of the response to pharmacological stimulation).

    Time frame: Day of blood sample (inclusion visit)

  5. Comparison of the inflammatory profile of PBMC from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF

    The inflammatory profile will evaluate by flow cytometry the proportion of the different populations of monocytes and lymphocytes using several labeling antibodies.

    Time frame: Day of blood sample (inclusion visit)

07

Study locations

1 of 1 sites recruiting
  • Hopital Louis Pradel
    Bron, 69677, France
    Recruiting
    • Hélène Thibault, PU,PH · ContactHelene.thibault@chu-lyon.fr · 04427856691
    • Hélène Thibault, PU,PH · Principal investigator
    • Cyrille BERGEROT, MD, PhD · Sub investigator
    • Sybil CHARRIERE, PU,PH · Sub investigator
    • Laurent SEBBAG, PU,PH · Sub investigator
    • Nathan MEWTON, PU,PH · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2028, 60 months after the start.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 60 months is above that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 15, 2022
StartActual
May 23, 2023
Primary completionEst.
May 23, 2028
CompletionEst.
May 23, 2028
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05651919
Responsible party
Sponsor
First posted
Dec 15, 2022
Start date
May 23, 2023
Primary completion
May 23, 2028 (estimated)
Completion
May 23, 2028 (estimated)
Last update
Mar 27, 2026

Study contacts

Hélène THIBAULT, PU,PH
Contact
Helene.thibault@chu-lyon.fr
0427856691 ext. +33
Julia CANTERINI
Contact
Julia.canterini@chu-lyon.fr
0427856628 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion